Table 2.

Multivariate analysis of gene modules and subtypes in relation to patient post-relapse survival

	Long-term breast cancer-specific survival			Short-term breast cancer-specific survivalb
	HR	95% CI	P value	HR	95% CI	P value
Modulea (n = 111)
ESR1 lowc	1.3	0.8–2.1	0.27	2.2	1.2–4.2	0.01
ERBB2 highd	0.8	0.5–1.4	0.46	0.8	0.4–1.5	0.47
AURKA highd	1.2	0.8–2.0	0.38	1.1	0.5–2.1	0.89
PLAU highd	1.2	0.7–1.9	0.52	1.4	0.8–2.7	0.25
VEGF lowc	1.0	0.6–1.6	0.95	1.5	0.8–2.8	0.21
STAT1 lowc	1.0	0.6–1.6	0.99	0.8	0.4–1.6	0.58
CASP3 lowc	2.7	1.7–4.5	<0.001	2.2	1.1–4.1	0.02
PAM50a (n = 105)
Luminal A (Ref.)	1.0	–	–	1.0	–	–
Luminal B	2.3	0.8–6.9	0.12	2.4	0.3–19.5	0.42
HER2-enriched	4.4	1.5–12.8	0.01	7.6	1.0–58.2	0.05
Basal-like	3.7	1.3–10.9	0.02	7.2	1.0–54.6	0.06

^aAdjusted for age at diagnosis, diagnosis date, and treatment received.

^b1.5-year survival.

^cIntermediate/high as reference group.

^dLow/intermediate as reference group.

HR, hazard ratio; CI, confidence interval.